BIOLASE Inc (NASDAQ:BIOL) – Analysts at Dougherty & Co dropped their FY2019 earnings per share (EPS) estimates for shares of BIOLASE in a research note issued to investors on Thursday, November 7th. Dougherty & Co analyst K. Bauser now expects that the medical technology company will post earnings per share of ($0.69) for the year, down from their prior forecast of ($0.63). Dougherty & Co also issued estimates for BIOLASE’s Q4 2019 earnings at ($0.06) EPS and FY2020 earnings at ($0.36) EPS.

BIOLASE (NASDAQ:BIOL) last released its quarterly earnings data on Wednesday, November 6th. The medical technology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.13. The business had revenue of $8.65 million during the quarter. BIOLASE had a negative net margin of 47.46% and a negative return on equity of 159.26%.

A number of other analysts have also weighed in on BIOL. Ascendiant Capital Markets set a $3.00 price objective on shares of BIOLASE and gave the company a “buy” rating in a research note on Monday, August 12th. Zacks Investment Research lowered shares of BIOLASE from a “hold” rating to a “sell” rating in a research note on Monday. Finally, ValuEngine upgraded shares of BIOLASE from a “hold” rating to a “buy” rating in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $2.17.

NASDAQ:BIOL opened at $0.51 on Monday. The firm has a market cap of $12.73 million, a P/E ratio of -0.60 and a beta of 2.19. The company has a debt-to-equity ratio of 3.51, a quick ratio of 1.11 and a current ratio of 2.04. BIOLASE has a fifty-two week low of $0.46 and a fifty-two week high of $2.87. The firm has a 50-day simple moving average of $0.76 and a two-hundred day simple moving average of $1.37.

In other news, major shareholder Larry N. Feinberg acquired 17,391 shares of BIOLASE stock in a transaction on Tuesday, October 29th. The stock was acquired at an average cost of $57.50 per share, for a total transaction of $999,982.50. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 4.50% of the stock is currently owned by company insiders.

An institutional investor recently raised its position in BIOLASE stock. Vanguard Group Inc. grew its stake in shares of BIOLASE Inc (NASDAQ:BIOL) by 487.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 958,247 shares of the medical technology company’s stock after acquiring an additional 795,067 shares during the quarter. Vanguard Group Inc. owned about 4.50% of BIOLASE worth $1,408,000 as of its most recent SEC filing. 37.73% of the stock is owned by institutional investors and hedge funds.

BIOLASE Company Profile

BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening.

Further Reading: How is the LIBOR rate calculated?

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.